The administration of IFN-α, a Th1 cytokine, is a well-known efficient treatment in advanced-stage CTCL [100,272,273,274], and its therapeutic action, at least in part, is related to restoring the host’s immune system action against the disease. Here, IFNA1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.